NYSE:QGEN

QIAGEN Stock Forecast, Price & News

$47.87
+0.15 (+0.31 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$47.51
$47.92
50-Day Range
$46.28
$52.75
52-Week Range
$42.22
$59.00
Volume447,315 shs
Average Volume805,119 shs
Market Capitalization$10.91 billion
P/E Ratio24.93
Dividend YieldN/A
Beta0.25
30 days | 90 days | 365 days | Advanced Chart
Receive QGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for QIAGEN and its competitors with MarketBeat's FREE daily newsletter.


QIAGEN logo

About QIAGEN

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay (IGRA) for TB testing, and assays for post-transplant testing and viral load monitoring; assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and assays for prenatal testing and detection of sexually transmitted diseases and HPV; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers PCR consumables, such as quantitative PCR, reverse transcription and combinations kits for analysis of gene expression, genotyping and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. It offers predefined and custom NGS gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.54 out of 5 stars

Medical Sector

417th out of 2,096 stocks

Biological Products, Except Diagnostic Industry

50th out of 196 stocks

Analyst Opinion: 3.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











QIAGEN (NYSE:QGEN) Frequently Asked Questions

Is QIAGEN a buy right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for QIAGEN in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" QIAGEN stock.
View analyst ratings for QIAGEN
or view top-rated stocks.

What stocks does MarketBeat like better than QIAGEN?

Wall Street analysts have given QIAGEN a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but QIAGEN wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is QIAGEN's next earnings date?

QIAGEN is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for QIAGEN
.

How were QIAGEN's earnings last quarter?

QIAGEN (NYSE:QGEN) released its earnings results on Sunday, May, 2nd. The company reported $0.66 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.63 by $0.03. The business earned $567.21 million during the quarter, compared to analyst estimates of $557.57 million. QIAGEN had a trailing twelve-month return on equity of 21.06% and a net margin of 21.72%. During the same quarter in the previous year, the company earned $0.34 earnings per share.
View QIAGEN's earnings history
.

How has QIAGEN's stock been impacted by COVID-19?

QIAGEN's stock was trading at $41.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, QGEN stock has increased by 16.5% and is now trading at $47.87.
View which stocks have been most impacted by COVID-19
.

What guidance has QIAGEN issued on next quarter's earnings?

QIAGEN issued an update on its FY 2021 earnings guidance on Monday, May, 17th. The company provided earnings per share guidance of 2.420-2.460 for the period, compared to the Thomson Reuters consensus estimate of $2.490. The company issued revenue guidance of $2.21 billion-$2.24 billion, compared to the consensus revenue estimate of $2.27 billion.

What price target have analysts set for QGEN?

15 brokerages have issued 1-year price targets for QIAGEN's shares. Their forecasts range from $52.00 to $66.00. On average, they expect QIAGEN's share price to reach $59.67 in the next year. This suggests a possible upside of 24.6% from the stock's current price.
View analysts' price targets for QIAGEN
or view top-rated stocks among Wall Street analysts.

Who are QIAGEN's key executives?

QIAGEN's management team includes the following people:
  • Mr. Thierry Bernard, CEO, MD & Member of Management Board (Age 56, Pay $2.41M)
  • Dr. Roland Sackers, CFO, MD & Member of Management Board (Age 52, Pay $977.5k)
  • Dr. Barthold Piening, Sr. VP & Head of Global Operations (Age 63)
  • Mr. John Gilardi, VP of Corp. Communications & Investor Relations
  • Ms. Stephany Foster, SVP & Head of HR
  • Mr. Peer Michael Schatz, Sr. Advisor (Age 55)
  • Dr. Thomas Schweins, Sr. VP of Life Science Bus. Area
  • Dr. Thomas Theuringer, Sr. Director & Head of External Communications
  • Mr. Jean-Pascal Viola, SVP, Head of the Molecular Diagnostics Bus. Area and Co. Bus Dev Intellectual Propty & Litigation
  • Dr. Jonathan G. Sheldon Ph.D., Sr. VP of Qiagen Digital Insights Bus. Area (Age 49)

What is Thierry Bernard's approval rating as QIAGEN's CEO?

33 employees have rated QIAGEN CEO Thierry Bernard on Glassdoor.com. Thierry Bernard has an approval rating of 65% among QIAGEN's employees.

Who are some of QIAGEN's key competitors?

What other stocks do shareholders of QIAGEN own?

Based on aggregate information from My MarketBeat watchlists, some companies that other QIAGEN investors own include NVIDIA (NVDA), QUALCOMM (QCOM), Gilead Sciences (GILD), Advanced Micro Devices (AMD), PayPal (PYPL), Netflix (NFLX), Pfizer (PFE), Cisco Systems (CSCO), Amgen (AMGN) and Lam Research (LRCX).

What is QIAGEN's stock symbol?

QIAGEN trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

Who are QIAGEN's major shareholders?

QIAGEN's stock is owned by many different retail and institutional investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (7.17%), FIL Ltd (2.30%), BlackRock Inc. (2.15%), Millennium Management LLC (1.68%), Goldman Sachs Group Inc. (1.00%) and DekaBank Deutsche Girozentrale (0.96%).

Which institutional investors are selling QIAGEN stock?

QGEN stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd, Millennium Management LLC, Morgan Stanley, Bank of Montreal Can, Barclays PLC, D. E. Shaw & Co. Inc., Schonfeld Strategic Advisors LLC, and DekaBank Deutsche Girozentrale.

Which institutional investors are buying QIAGEN stock?

QGEN stock was purchased by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Senator Investment Group LP, Goldman Sachs Group Inc., Janus Henderson Group PLC, Aviva PLC, Korea Investment CORP, BlackRock Inc., and Russell Investments Group Ltd..

How do I buy shares of QIAGEN?

Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is QIAGEN's stock price today?

One share of QGEN stock can currently be purchased for approximately $47.87.

How much money does QIAGEN make?

QIAGEN has a market capitalization of $10.91 billion and generates $1.87 billion in revenue each year. The company earns $359.19 million in net income (profit) each year or $2.15 on an earnings per share basis.

How many employees does QIAGEN have?

QIAGEN employs 5,610 workers across the globe.

What is QIAGEN's official website?

The official website for QIAGEN is www.qiagen.com.

Where are QIAGEN's headquarters?

QIAGEN is headquartered at HULSTERWEG 82, VENLO P7, 5912.

How can I contact QIAGEN?

QIAGEN's mailing address is HULSTERWEG 82, VENLO P7, 5912. The company can be reached via phone at 31-77-355-6600 or via email at [email protected]


This page was last updated on 6/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.